Last reviewed · How we verify
diltiazem and acetylcystein
This combination uses diltiazem to reduce calcium influx and improve cardiac function while acetylcysteine provides antioxidant and mucolytic support to protect against drug-induced injury.
This combination uses diltiazem to reduce calcium influx and improve cardiac function while acetylcysteine provides antioxidant and mucolytic support to protect against drug-induced injury. Used for Investigational combination therapy in phase 3 (specific indication not publicly detailed).
At a glance
| Generic name | diltiazem and acetylcystein |
|---|---|
| Also known as | Combined diltiazem and acetylcystein drug group |
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Calcium channel blocker + antioxidant combination |
| Target | L-type calcium channel (diltiazem); glutathione synthesis pathway (acetylcysteine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Diltiazem is a non-dihydropyridine calcium channel blocker that decreases intracellular calcium, reducing cardiac contractility and heart rate, commonly used for arrhythmias and angina. Acetylcysteine is a thiol-containing antioxidant that replenishes glutathione stores and scavenges reactive oxygen species, potentially protecting tissues from oxidative stress and drug toxicity. The combination may be investigated for cardioprotection or to mitigate diltiazem-related adverse effects in specific cardiac conditions.
Approved indications
- Investigational combination therapy in phase 3 (specific indication not publicly detailed)
Common side effects
- Headache (diltiazem)
- Dizziness (diltiazem)
- Constipation (diltiazem)
- Nausea (acetylcysteine)
- Rash (acetylcysteine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- diltiazem and acetylcystein CI brief — competitive landscape report
- diltiazem and acetylcystein updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI